Answers are grounded in this paper and cite their sources.
Cost-effectiveness of influenza vaccination varied by age and risk status and was less than $95,000/QALY for all subgroups, except for non-high-risk working-age adults. Results were sensitive to the probability of influenza illness and vaccination was more favorable under certain scenarios. Vaccination for higher risk subgroups resulted in ICERs below $100,000/QALY even at low levels of vaccine effectiveness or circulating virus.
No takes yet. Share an insight, caveat, or question.
DeLuca et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: